指南与共识消化系统肿瘤

结直肠癌评估的分子生物标志物:美国临床病理学会、美国病理学家学会、分子病理学协会和美国临床肿瘤学会指南

Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology.
指南 / 共识 · J Clin Oncol · 2017-02-06

该指南由ASCP、CAP、AMP和ASCO专家小组基于超过4000篇文献的系统综述制定,共形成21条指南声明(8条推荐、10条专家共识意见和3条无推荐)。推荐对EGFR信号通路基因进行突变检测,因其可作为抗EGFR单克隆抗体治疗获益的阴性预测标志物,并涉及检测方法、标本类型、检测时机和周转时间等实验室操作。

要点

  • 推荐对结直肠癌EGFR信号通路基因进行突变检测,作为抗EGFR单克隆抗体治疗获益的阴性预测标志物。
  • 部分生物标志物突变具有明确的预后价值。
  • 分子检测的实验室操作涉及检测方法选择、标本类型、检测申请时机和结果周转时间。

核心结论

  • 证据支持对EGFR信号通路基因进行突变检测,因其提供临床可操作信息,作为抗EGFR单克隆抗体治疗获益的阴性预测标志物。
  • 部分生物标志物突变具有明确的预后价值。

研究设计与样本

  • 由美国临床病理学会(ASCP)、美国病理学家学会(CAP)、分子病理学协会(AMP)和美国临床肿瘤学会(ASCO)召集专家小组制定循证指南。
  • 进行了包括超过4000篇文章的综合文献检索以收集数据。

主要发现

  • 共建立21条指南声明,包括8条推荐、10条专家共识意见和3条无推荐。

关键数值与推荐

  • 推荐对EGFR信号通路基因进行突变检测,作为抗EGFR单克隆抗体治疗获益的阴性预测标志物(推荐)。
  • 部分生物标志物突变具有明确的预后价值(推荐)。
  • 分子检测的实验室操作涉及检测方法选择、标本类型、检测申请时机和结果周转时间(推荐)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Molecular testing of colorectal cancers (CRCs) to improve patient care and outcomes of targeted and conventional therapies has been the center of many recent studies, including clinical trials. Evidence-based recommendations for the molecular testing of CRC tissues to guide epidermal growth factor receptor (EGFR) -targeted therapies and conventional chemotherapy regimens are warranted in clinical practice. The purpose of this guideline is to develop evidence-based recommendations to help establish standard molecular biomarker testing for CRC through a systematic review of the literature. Methods The American Society for Clinical Pathology (ASCP), College of American Pathologists (CAP), Association for Molecular Pathology (AMP), and the American Society of Clinical Oncology (ASCO) convened an Expert Panel to develop an evidence-based guideline to help establish standard molecular biomarker testing, guide targeted therapies, and advance personalized care for patients with CRC. A comprehensive literature search that included over 4,000 articles was conducted to gather data to inform this guideline. Results Twenty-one guideline statements (eight recommendations, 10 expert consensus opinions and three no recommendations) were established. Recommendations Evidence supports mutational testing for genes in the EGFR signaling pathway, since they provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC. Mutations in several of the biomarkers have clear prognostic value. Laboratory approaches to operationalize molecular testing for predictive and prognostic molecular biomarkers involve selection of assays, type of specimens to be tested, timing of ordering of tests and turnaround time for testing results. Additional information is available at: www.asco.org/CRC-markers-guideline and www.asco.org/guidelineswiki.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Sepulveda AR, Hamilton SR, Allegra CJ, et al. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017. PMID: 28165299. doi:10.1200/JCO.2016.71.9807

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。